H.C. Wainwright analyst Douglas Tsao downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Neutral with a price target of $36.50.

For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.

Shares of Pacira Pharmaceuticals closed at $36.39 yesterday.